Pfizer (PFE) Tops Q3 EPS by 21c, Misses on Revenue; Offers FY25 Guidance

Pfizer (NYSE: PFE) reported Q3 EPS of $0.87, $0.21 better than the analyst estimate of $0.66. Revenue for the quarter came in at $16.7 billion versus the consensus estimate of $16.8 billion.

GUIDANCE:

Pfizer sees FY2025 EPS of $3.00-$3.15, versus the consensus of $3.04. Pfizer sees FY2025 revenue of $61-64 billion, versus the consensus of $62.8 billion.

For earnings history and earnings-related data on Pfizer (PFE) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• INVO Fertility (IVF) Tops Q2 EPS by 105c
• Stifel on EyePoint Inc. (EYPT): 'we think these data bode well for LUCIA (expected October) barring another unusual asymmetry'